Efficacy of voriconazole in a murine model of acute Trypanosoma cruzi infection.

OBJECTIVES Antifungal triazole derivatives have been studied as possible alternatives for the treatment of Chagas' disease. Voriconazole has demonstrated in vitro activity against Trypanosoma cruzi, but its efficacy in vivo has not yet been tested. We aimed to determine the effect of voriconazole in a murine model of acute T. cruzi infection. METHODS Treatment efficacy was evaluated by comparing parasitaemia, mortality and organ involvement (by histological examination) of infected mice. RESULTS Treatment with voriconazole significantly lowered parasitaemia and mortality compared with controls, reduced the percentage of mice with amastigote nests in heart and skeletal muscle and moderately decreased myocardial inflammation. CONCLUSIONS Our findings support the potential of voriconazole for the treatment of acute Chagas' disease and motivate future animal studies using varying doses and treatment schemes. Further evaluation of voriconazole for clinical use in human Chagas' patients is warranted.

[1]  F. Buckner,et al.  Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease. , 2012, International journal for parasitology. Drugs and drug resistance.

[2]  G. Meyfroidt,et al.  Voriconazole plasma levels in children are highly variable , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[3]  J. Altcheh,et al.  Adverse Events After the Use of Benznidazole in Infants and Children With Chagas Disease , 2011, Pediatrics.

[4]  H. Jafri,et al.  Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children , 2010, Antimicrobial Agents and Chemotherapy.

[5]  M. Chung,et al.  Hydroxymethylnitrofurazone Is Active in a Murine Model of Chagas' Disease , 2010, Antimicrobial Agents and Chemotherapy.

[6]  D. Niederwieser,et al.  Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients , 2010, Antimicrobial Agents and Chemotherapy.

[7]  W. Degrave,et al.  In vitro and in vivo experimental models for drug screening and development for Chagas disease. , 2010, Memorias do Instituto Oswaldo Cruz.

[8]  M. G. Álvarez,et al.  Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities , 2009, Expert review of anti-infective therapy.

[9]  J. Jannin,et al.  An overview of Chagas disease treatment. , 2007, Memorias do Instituto Oswaldo Cruz.

[10]  J. Urbina,et al.  Comparative Efficacies of TAK-187, a Long-Lasting Ergosterol Biosynthesis Inhibitor, and Benznidazole in Preventing Cardiac Damage in a Murine Model of Chagas' Disease , 2005, Antimicrobial Agents and Chemotherapy.

[11]  J. Urbina,et al.  Activity of the New Triazole Derivative Albaconazole against Trypanosoma (Schizotrypanum) cruzi in Dog Hosts , 2004, Antimicrobial Agents and Chemotherapy.

[12]  Steve A. Hernandez,et al.  Improving the mouse model for studying the efficacy of voriconazole. , 2003, The Journal of antimicrobial chemotherapy.

[13]  T. Araújo-Jorge,et al.  Benznidazole Treatment following Acute Trypanosoma cruzi Infection Triggers CD8+ T-Cell Expansion and Promotes Resistance to Reinfection , 2002, Antimicrobial Agents and Chemotherapy.

[14]  A. Sugar,et al.  Efficacy of Voriconazole in Treatment of Murine Pulmonary Blastomycosis , 2001, Antimicrobial Agents and Chemotherapy.

[15]  O. Martins-Filho,et al.  A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. , 2000, The Journal of antimicrobial chemotherapy.

[16]  D. Loebenberg,et al.  Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan ParasiteTrypanosoma (Schizotrypanum) cruzi in Immunocompetent and Immunosuppressed Murine Hosts , 2000, Antimicrobial Agents and Chemotherapy.

[17]  R. Tarleton,et al.  Depletion of T-cell subpopulations results in exacerbation of myocarditis and parasitism in experimental Chagas' disease , 1994, Infection and immunity.

[18]  W. Gutteridge,et al.  A/JAX inbred mice in chemotherapeutic investigations of experimental Chagas' disease. , 1978, Annals of tropical medicine and parasitology.

[19]  W. H. Kyle,et al.  Growth of the laboratory mouse , 1968, Theoretical and Applied Genetics.

[20]  Z. Brener.  Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. , 1962, Revista do Instituto de Medicina Tropical de Sao Paulo.

[21]  F. Buckner,et al.  Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. , 2008, Advances in experimental medicine and biology.

[22]  A. Romanha,et al.  In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. , 2003, International journal of antimicrobial agents.

[23]  Tropical disease research , 2000, Releve epidemiologique hebdomadaire.

[24]  José Milei,et al.  Enfermedad de Chagas , 1994 .

[25]  A. Rowan.  Guide for the Care and Use of Laboratory Animals , 1979 .